One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?.
doi : 10.1200/JCO-25-01439
Volume 43(29) pgs. 3141-3231 October 10, 2025
APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy.
doi : 10.1200/JCO-25-01496
Brain Imaging Surveillance for Patients With Metastatic Breast Cancer: A Randomized Clinical Trial Is Required to Guide Practice.
doi : 10.1200/JCO-25-00356
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.
doi : 10.1200/JCO-25-00486
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
doi : 10.1200/JCO-25-00535
Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).
doi : 10.1200/JCO-24-02644
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.
doi : 10.1200/JCO-25-01003
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
doi : 10.1200/JCO-25-00788
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.
doi : 10.1200/JCO-25-00272
Second Mitochondrial Activator of Caspases Mimetics Accelerate Progression of Locally Advanced Head and Neck Cancer.
doi : 10.1200/JCO-25-01024
Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib.
doi : 10.1200/JCO-25-00967
Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?.
doi : 10.1200/JCO-25-01055
Reply to: "Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib" and "Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer: Promising Yet Premature?".
doi : 10.1200/JCO-25-01448
Recalibrating Digital Predictions: Uncovering the Limits of the MMAI Prostate LT-ADT Predictive Model in the Era of Tumor Evolution.
doi : 10.1200/JCO-25-01213
Reply to: Recalibrating Digital Predictions: Uncovering the Limits of the MMAI Prostate LT-ADT Predictive Model in the Era of Tumor Evolution.
doi : 10.1200/JCO-25-01303
Erratum: TAR-200 for Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
doi : 10.1200/JCO-25-02053
